|
before treatment
|
after 1 week
|
after 6 weeks
|
after 12 weeks
|
---|
|
Number of patients
|
Number of patients
|
Number of patients
|
Number of patients
|
---|
CD
|
18
|
18
|
18
|
18
|
UC
|
18
|
18
|
18
|
16
|
HS
|
38
|
--
|
--
|
--
|
C3-AC, alternative
|
% of standard
|
% of standard
|
% of standard
|
% of standard
|
CD
|
61.5 (53–82)
|
51.5 (49–71)
|
55.5 (49–70)
|
59 (49–75)
|
UC
|
58 (49–78)
|
49 (49–70)
|
49 (49–78)
|
59 (49–70)
|
HS
|
49 (49–67)
|
--
|
--
|
--
|
C3-AC, classical
|
% of standard
|
% of standard
|
% of standard
|
% of standard
|
CD
|
109 (81–172)
|
97.5 (39–124)
|
94.5 (70–141)
|
99.5 (53–143)
|
UC
|
97 (39–148)
|
88 (58–129)
|
91 (59–115)
|
94 (39–160)
|
HS
|
82.5 (68–108)
|
--
|
--
|
--
|
MBL-concentration
|
ng/ml
|
ng/ml
|
ng/ml
|
ng/ml
|
CD
|
3251 (14 – 6085)
|
3071 (10 – 4636)
|
2911 (10 – 5178)
|
3257 (10 – 4718)
|
UC
|
1082 (6 – 3926)
|
1171 (3 – 4845)
|
1141 (3 – 4590)
|
1292 (3 – 4147)
|
HS
|
1219 (2 – 3577)
|
--
|
--
|
--
|
MBL-C4-AC
|
% of standard
|
% of standard
|
% of standard
|
% of standard
|
CD
|
118 (21–187)
|
63 (25–192)
|
62.5 (21–163)
|
87 (17–192)
|
UC
|
54 (12–201)
|
54 (11–192)
|
45 (9–163)
|
55 (12–192)
|
HS
|
66.5 (9–162)
|
--
|
--
|
--
|
- Median and range (in parenthesis) of alternative and classical pathway-mediated C3-activation capacity(C3-AC), mannan-binding lectin (MBL) concentration, MBL-C4-AC.